U.S. pharmaceutical giant Eli Lilly & Co. (LLY) has become the latest company to achieve a $1 trillion market capitalization.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The milestone was reached shortly after U.S. markets opened on Nov. 21. LLY stock is up a little more than 1% to start the trading day, pushing its share price to an all-time high of $1,061.00 and giving the company a market capitalization of $1 trillion.
Eli Lilly is one of the few non-technology companies to have a market cap of $1 trillion or greater. It joins holding company Berkshire Hathaway (BRK.B) and commercial bank JPMorgan Chase (JPM) as the only companies outside the technology sector to achieve the lofty valuation.
LLY Stock Split
Hitting the $1 trillion market cap milestone is helping to fuel speculation that Eli Lilly might soon split its stock. With the shares trading above $1,000 each, analysts say a stock split could help make them more affordable to individual retail investors and attract more buyers.
LLY stock is expected to continue running higher as the company’s current weight-loss drug Zepbound is a global bestseller. The share price is likely to get a further boost in 2026 as Eli Lilly rolls out a new weight-loss pill and ramps up production of its obesity treatments
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 18 Buy and two Hold recommendations issued in the last three months. The average LLY price target of $1,042.89 implies 0.47% downside from current levels.
